🏢 官网IREWTXQwen · 实盘不做把握 4/10不做原因:已被定价
北京时间·🕒 发布 08-24 20:00:00·⟳ 抓取 08-27 12:14:46·⚡ 决策 08-26 17:49:06 −18h25m·62.6 天前
Edgewise Therapeutics宣布CIRRUS-HCM研究入选ESC 2026 Late-Breaking Science，预告EDG-7500治疗HCM的12周II期数据积极
事件方向积极但已高度price-in：股价13周从100涨至129（+29%），距52周高仅-8.7%，事件日反应仅+1.22%。本条是演示预告（实际数据8月31日），非数据发布本身；'positive top-line'语言虽新但市场已通过前期CIRRUS数据和入选预期充分定价。剩余催化（8/31演示）携带二元风险，风险收益不对称。
📄 原文EWTX↗ 原文
– Presentation highlights positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and…
不做 Edgewise Therapeutics（EWTX.US）
事件为演示预告而非数据发布本身，'positive top-line'语言虽方向积极但股价已充分反映（13周+29%、距52周高仅-8.7%、事件日仅+1.22%）。实际数据8月31日才发布，剩余催化携带二元风险且增量信息有限，风险收益不对称。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Edgewise宣布CIRRUS-HCM入选ESC Late-Breaking Science并预告12周II期数据积极。方向明确利好，但：①股价已从52周低$13.7涨至$44.2（+223%），近52周高仅-8.7%；②事件日仅+1.22%，反应平淡；③这是演示预告而非数据本身，实际数据8月31日才发布；④8月4日已有一次+16.5%的大涨（可能对应早期CIRRUS数据）。综合判断本条催化的增量信息已被前期走势充分定价，剩余空间有限而二元风险仍在。
🔎 新鲜度:最早出现 2026-08-24 · 扩散 medium · price-in 风险 high ↗
消息传播链
- 公司IR一手发布，宣布ESC Late-Breaking Science入选并预告积极topline数据市场反应:当日EWTX收盘+1.22%（$44.72），反应平淡
主要风险
- 实际数据8月31日才发布，若完整数据不及topline预期或安全性信号出现，股价可能大幅回落
- 股价已近52周高，拥挤度高，任何负面信号可能引发快速抛售
反向证据
- 做多前查反向 · 来源 price_snapshot · 日期 2026-08-25 · 影响 weakens
13周轨迹从100升至129（+29%），8月4日单日+16.48%，事件日仅+1.22%；股价已近52周高-8.7%，表明市场已持续交易该故事
检索:EWTX EDG-7500 CIRRUS-HCM price-in risk prior data already known
先例如何影响了这次决策
对本次决策的影响:先例缺失不影响最终AVOID结论，因为price-in证据已充分；但若有先例可能改变置信度
方向:无法确定——Web搜索不可用，无法检索外部同类先例
涨幅量级:无可用高相似先例校准幅度
形态:无法判断
工具调用 · 历史记录,结果未知(7 种)
- fetch_decision_experience · 结果未知
- search_processed_events · 结果未知
- stock_quote · 结果未知
- web_search · 结果未知
- search_case_library · 结果未知
- price_snapshot · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 4,007 字
– Presentation highlights positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) –
BOULDER, Colo.
,
Aug. 24, 2026
/PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that the CIRRUS-HCM abstract was selected for a late-breaking science presentation at the European Society of Cardiology (ESC) Congress, taking place August 28-31 in Munich, Germany. EDG-7500 is a novel, oral, selective cardiac sarcomere modulator designed to slow early contraction and improve cardiac relaxation in symptomatic HCM while preserving systolic function.
Late-Breaking Science Presentation:
Title:
CIRRUS-HCM: 12-Week Evaluation of the Safety and Efficacy of the Novel Cardiac Sarcomere Modulator EDG-7500 in Nonobstructive and Obstructive Hypertrophic Cardiomyopathy
Presenter:
Anjali Tiku Owens, M.D., Associate Professor of Medicine in the Division of Cardiology at the Perelman School of Medicine of the University of Pennsylvania
Date:
Monday, August 31, 2026, 11:30 – 11:45 am CEST
Session:
Transforming the heart: novel therapies for myocardial disease and heart failure
Location:
Achgabat (Hall A3)
The presentation will be available on the Edgewise
website
after it is presented.
About CIRRUS-HCM
CIRRUS-HCM is a multi-part, open label trial of EDG-7500 in participants with obstructive and nonobstructive HCM at over 20 clinical sites in the U.S. Part A of the trial evaluated the safety and tolerability of a single oral dose of EDG-7500 in participants with obstructive HCM (oHCM). Parts B and C evaluated fixed doses of EDG-7500 over 28 days in oHCM and nonobstructive HCM (nHCM), respectively; the results can be found
here
. Part D is a 12-week study including participants with oHCM and nHCM designed to explore dose response and optimization, followed by an open-label extension; the results can be found
here
. To learn more about CIRRUS-HCM, visit
clinicaltrials.gov
,
NCT06347159
.
About Hypertrophic Cardiomyopathy
HCM is the most common form of genetic heart disease, affecting approximately one in 500 people, and is associated with reduced quality of life and an elevated risk of heart failure, abnormal heart rhythms, and sudden cardiac death. Individuals with HCM can become extremely limited in their functional capacity and ability to perform the activities of daily living. Commonly experienced symptoms include breathlessness, irregular heartbeat, chest pain, tiredness, dizziness, or even fainting. These symptoms are caused by excessive contraction and thickening (hypertrophy) of the left ventricular wall of the heart. Over time, the thickened muscle becomes stiff, making it difficult for the heart to relax and fill with blood (diastolic dysfunction). There are two major forms of HCM: obstructive and nonobstructive. Despite advancements in treatment options for some patients with HCM, there remains a significant unmet need for additional therapeutic approaches for patients.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading biopharmaceutical company focused on developing innovative therapies for serious cardiovascular and cardiometabolic diseases. Leveraging its expertise in integrated muscle physiology and small molecule drug development, Edgewise is advancing a cardiovascular pipeline targeting significant unmet needs, including hypertrophic cardiomyopathy and heart failure. To learn more, go to
edgewisetx.com
or follow Edgewise on
LinkedIn
,
X
,
Facebook
and
Instagram
.
This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.
View original content to download multimedia:
https://www.prnewswire.com/news-releases/edgewise-therapeutics-announces-upcoming-late-breaking-science-presentation-at-the-european-society-of-cardiology-esc-congress-2026-302857842.html
SOURCE Edgewise Therapeutics
BOULDER, Colo.
,
Aug. 24, 2026
/PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that the CIRRUS-HCM abstract was selected for a late-breaking science presentation at the European Society of Cardiology (ESC) Congress, taking place August 28-31 in Munich, Germany. EDG-7500 is a novel, oral, selective cardiac sarcomere modulator designed to slow early contraction and improve cardiac relaxation in symptomatic HCM while preserving systolic function.
Late-Breaking Science Presentation:
Title:
CIRRUS-HCM: 12-Week Evaluation of the Safety and Efficacy of the Novel Cardiac Sarcomere Modulator EDG-7500 in Nonobstructive and Obstructive Hypertrophic Cardiomyopathy
Presenter:
Anjali Tiku Owens, M.D., Associate Professor of Medicine in the Division of Cardiology at the Perelman School of Medicine of the University of Pennsylvania
Date:
Monday, August 31, 2026, 11:30 – 11:45 am CEST
Session:
Transforming the heart: novel therapies for myocardial disease and heart failure
Location:
Achgabat (Hall A3)
The presentation will be available on the Edgewise
website
after it is presented.
About CIRRUS-HCM
CIRRUS-HCM is a multi-part, open label trial of EDG-7500 in participants with obstructive and nonobstructive HCM at over 20 clinical sites in the U.S. Part A of the trial evaluated the safety and tolerability of a single oral dose of EDG-7500 in participants with obstructive HCM (oHCM). Parts B and C evaluated fixed doses of EDG-7500 over 28 days in oHCM and nonobstructive HCM (nHCM), respectively; the results can be found
here
. Part D is a 12-week study including participants with oHCM and nHCM designed to explore dose response and optimization, followed by an open-label extension; the results can be found
here
. To learn more about CIRRUS-HCM, visit
clinicaltrials.gov
,
NCT06347159
.
About Hypertrophic Cardiomyopathy
HCM is the most common form of genetic heart disease, affecting approximately one in 500 people, and is associated with reduced quality of life and an elevated risk of heart failure, abnormal heart rhythms, and sudden cardiac death. Individuals with HCM can become extremely limited in their functional capacity and ability to perform the activities of daily living. Commonly experienced symptoms include breathlessness, irregular heartbeat, chest pain, tiredness, dizziness, or even fainting. These symptoms are caused by excessive contraction and thickening (hypertrophy) of the left ventricular wall of the heart. Over time, the thickened muscle becomes stiff, making it difficult for the heart to relax and fill with blood (diastolic dysfunction). There are two major forms of HCM: obstructive and nonobstructive. Despite advancements in treatment options for some patients with HCM, there remains a significant unmet need for additional therapeutic approaches for patients.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading biopharmaceutical company focused on developing innovative therapies for serious cardiovascular and cardiometabolic diseases. Leveraging its expertise in integrated muscle physiology and small molecule drug development, Edgewise is advancing a cardiovascular pipeline targeting significant unmet needs, including hypertrophic cardiomyopathy and heart failure. To learn more, go to
edgewisetx.com
or follow Edgewise on
,
X
,
and
.
This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.
View original content to download multimedia:
https://www.prnewswire.com/news-releases/edgewise-therapeutics-announces-upcoming-late-breaking-science-presentation-at-the-european-society-of-cardiology-esc-congress-2026-302857842.html
SOURCE Edgewise Therapeutics
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。